

ENANTA PHARMACEUTICALS INC
Form 8-K
November 26, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 22, 2013

ENANTA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware **001-35839** **04-3205099**
(State or Other Jurisdiction of **(Commission File Number)** **(IRS Employer Identification No.)**
Incorporation)

500 Arsenal Street

Watertown, MA 02472

(Address of Principal Executive Offices) (Zip Code)

(617) 607-0800

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 22, 2013, Helmut M. Schühler submitted his resignation as a director of Enanta. In addition to his service on Enanta's Board of Directors, Dr. Schühler served as a member of the Board's Compensation Committee and its Nominating and Corporate Governance Committee. Dr. Schühler's resignation, which was effective immediately, is not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENANTA PHARMACEUTICALS, INC.

Dated: November 25, 2013

By: /s/ Paul J. Mellett
Paul J. Mellett

Chief Financial Officer